Lp-PLA2 and MPO: The FM Practitioner's Guide to Arterial Inflammation Markers

Your patient's LDL is 110. Their hs-CRP is 1.8. Traditional risk calculators say they're low to intermediate risk. You're not comfortable clearing them, but you're not sure what else to order.

Here's the problem. The standard inflammatory marker panel is missing half the picture. hs-CRP tells you about systemic inflammation, but it doesn't tell you what's happening inside the arterial wall. Studies show hs-CRP correlates poorly with coronary lesion severity on angiography, because systemic inflammation and vascular-specific inflammation are not the same thing (Razban MM et al., Clujul Med. 2016; PMID 27547050). For the arterial picture, you need Lp-PLA2 and MPO.

These are the two most important arterial-specific inflammatory markers in functional medicine. They tell you whether there's active inflammation in the vessel wall itself, not just in the body generally. That distinction changes how you manage cardiovascular risk.

Why Standard Inflammatory Markers Aren't Enough

hs-CRP is produced by the liver in response to IL-6. It reflects systemic inflammation anywhere in the body. High hs-CRP could mean arthritis, a gut infection, or obesity-related inflammation. It tells you the body is inflamed. It doesn't tell you the arteries are inflamed.

This matters because inflammation inside the arterial wall is what drives plaque formation and rupture. A patient can have moderate hs-CRP with significant arterial inflammation. Conversely, a patient with high hs-CRP from rheumatoid arthritis might have relatively quiet arteries. ESR and fibrinogen share the same limitation: they're systemic, not vascular-specific. IL-6 and TNF-alpha are mechanistically important but impractical for routine clinical use.

What we need are markers that specifically reflect what's happening in the vessel wall. Lp-PLA2 and MPO do exactly that.

Lp-PLA2: The Plaque-Specific Inflammation Marker

Lipoprotein-associated phospholipase A2 (Lp-PLA2) is produced by monocytes and macrophages in the arterial wall and circulates bound primarily to LDL particles. Its pro-inflammatory role is mediated by the products of its reaction: lyso-phosphatidylcholine (lyso-PC) and oxidized non-esterified fatty acids (oxNEFAs), both of which amplify vascular inflammation (Zalewski A, Macphee C. Arterioscler Thromb Vasc Biol. 2005; PMID 15557304). The enzyme that evolved to clear oxidized phospholipids from LDL makes the inflammatory environment worse in the setting of oxidized LDL accumulation.

Lp-PLA2 is directly implicated in plaque vulnerability. Vulnerable plaques — the ones that rupture and cause heart attacks — are characterized by a large lipid core, thin fibrous cap, and active macrophage-driven inflammation. Lp-PLA2 is specifically concentrated in these plaques (PMID 15557304).

Reference ranges per Quest Diagnostics reference guidelines: <200 ng/mL desirable, 200-223 ng/mL borderline, >223 ng/mL elevated.

Lp-PLA2 is also clinically useful for its stability. Unlike hs-CRP, which fluctuates with acute infections, weight changes, and systemic conditions, Lp-PLA2 is more resistant to these confounders and reflects vascular inflammation more specifically over time.

Lp-PLA2 predicts cardiovascular events independently of traditional risk factors and hs-CRP (Lp-PLA2 Studies Collaboration; PMID 20031397). A note on clinical framing: while direct pharmacological inhibition of Lp-PLA2 with darapladib did not reduce major coronary events in the SOLID-TIMI 52 trial (O'Donoghue ML et al., JAMA. 2014; PMID 25173516), this does not invalidate Lp-PLA2 as a risk biomarker. The trial failure was drug-specific, not marker-specific. Lp-PLA2 remains a validated predictor of cardiovascular events; the darapladib results tell us that enzymatic inhibition alone is insufficient for cardiovascular protection, not that the marker lacks clinical meaning.

MPO: The Neutrophil Enzyme That Oxidizes LDL

Myeloperoxidase (MPO) is released by activated neutrophils and monocytes. Designed to kill pathogens via oxidative burst, it becomes harmful when activated in the arterial wall. MPO uses hydrogen peroxide and chloride to produce hypochlorous acid (HOCl), which oxidizes LDL and makes it more atherogenic, consumes nitric oxide and impairs endothelial function, degrades HDL and reduces its protective capacity, and directly damages the vascular wall. LDL modified by MPO-derived HOCl is present in atherosclerotic lesions and drives endothelial dysfunction including nitric oxide impairment.

Reference ranges vary by laboratory but are typically expressed in pmol/L. Values below 350 pmol/L are generally considered desirable, with higher values indicating increasing cardiovascular risk (per Quest Diagnostics reference guidelines).

MPO predicts cardiovascular events independently of traditional risk factors, hs-CRP, and troponin. It can be elevated in acute coronary syndrome before troponin rises, identifying myocardial injury in its earliest inflammatory stages.

MPO elevation should be interpreted in clinical context: acute infection, autoimmune disease, and intense exercise can also raise it. In the appropriate context, it remains a powerful vascular-specific risk signal.

How Lp-PLA2 and MPO Differ from CRP

The fundamental distinction is specificity. hs-CRP and ESR are systemic inflammation markers. Lp-PLA2 and MPO are vascular inflammation markers.

A patient with elevated hs-CRP but normal Lp-PLA2 and MPO may have systemic inflammation from autoimmune disease or infection without active arterial inflammation. A patient with normal hs-CRP but elevated Lp-PLA2 and MPO has arterial-specific inflammation the standard panel is missing.

Lp-PLA2 is also more resistant to the confounders that inflate hs-CRP, such as obesity, acute infections, and systemic autoimmune conditions, making it more interpretively stable across serial measurements.

The 6 Inflammatory Markers FM Practitioners Should Know

I organize cardiovascular inflammatory markers into two categories.

Systemic markers (smoke detectors):

• hs-CRP: Standard. Generic systemic inflammation.
• ADMA (asymmetric dimethylarginine): Marker of endothelial dysfunction, predicts cardiovascular events by impairing nitric oxide production.
• MACR (malondialdehyde-acetaldehyde adduct): Reflects oxidative stress and general oxidative damage.
• OxLDL (oxidized LDL): Direct measurement of LDL oxidation. The downstream product of MPO activity on LDL.

Vascular-specific markers (fire alarms):

• Lp-PLA2: The plaque-specific enzyme. Reflects active inflammation in the arterial wall creating vulnerable plaques.
• MPO: The neutrophil activation marker. Reflects active oxidation of LDL in the arterial wall.

Clinical workflow: start with hs-CRP as a screen. If elevated or borderline, add Lp-PLA2 and MPO for the arterial-specific picture. Add OxLDL if focused on oxidative stress. Add ADMA if assessing endothelial function directly.

When to Order Lp-PLA2 and MPO

Scenario 1: Intermediate risk with borderline hs-CRP. ASCVD score 5-7.5%, hs-CRP 1.2-2.0. Before deciding on statin therapy, Lp-PLA2 and MPO clarify whether arterial inflammation is present.

Scenario 2: Strong family history, normal cholesterol. Patient 45, LDL 130, father had MI at 52. Traditional calculators miss familial risk. These markers add arterial-specific data.

Scenario 3: Metabolic syndrome with borderline inflammatory markers. hs-CRP 1.8 in a patient with obesity, prediabetes, and hypertension. Quantify and track arterial inflammation over time.

Scenario 4: Post-event or post-procedure monitoring. After stent or MI. Track whether interventions are reducing arterial inflammation, not just LDL.

Scenario 5: Treatment response assessment. Patient on statin, fish oil, lifestyle program. Are the interventions working at the inflammation level?

Scenario 6: Comprehensive FM cardiovascular assessment. These markers complete the inflammatory dimension of a full cardiovascular workup.

Root Cause Approach: What Elevates These Markers

What elevates Lp-PLA2? Primarily LDL-bound oxidized phospholipids. Contributing factors: diet high in oxidized fats, smoking, diabetes, chronic systemic inflammation, and genetics.

What elevates MPO? Neutrophil activation in the arterial wall, driven by oxidized LDL, infection, autoimmune activity, and endothelial dysfunction. MPO is specifically elevated when LDL has been oxidized and the immune system is actively clearing it.

What lowers these markers?

Dietary interventions. Reduce oxidized fats (fried foods, processed oils). Increase omega-3 fatty acids from wild-caught fish — EPA and DHA reduce LDL oxidation and vascular inflammation, and observational and intervention data support omega-3 supplementation as a strategy for attenuating Lp-PLA2 activity. Add antioxidant-rich polyphenols: diets rich in polyphenols significantly inhibit LDL oxidation (Aviram M et al., Drugs Exp Clin Res. 2002; PMID 12224378). The overall evidence supports framing this as: diets rich in omega-3 fatty acids and antioxidant polyphenols reduce LDL oxidation and vascular inflammation, which may attenuate Lp-PLA2 and MPO activity.

Targeted supplementation. Omega-3 fatty acids (EPA/DHA) at therapeutic doses. Vitamin D optimization for immune regulation. Curcumin for direct anti-inflammatory effects on the vascular wall. CoQ10 to reduce oxidative stress.

Lifestyle. Smoking cessation is essential — smoking directly increases MPO activity. Moderate-intensity aerobic exercise reduces inflammatory markers. Stress management reduces cortisol and catecholamine-driven inflammation.

Treat underlying conditions. Managing diabetes, reducing visceral fat, treating gut dysbiosis, and addressing chronic infections all lower these markers. Arterial inflammation often reflects systemic inflammation elsewhere.

How HANS Handles Inflammatory Panel Documentation

HANS recognizes Lp-PLA2 and MPO as cardiovascular-specific markers, not generic elevations. A generic EMR logs "elevated inflammatory marker." HANS surfaces the clinical interpretation specific to each: Lp-PLA2 at 280 ng/mL means something different than hs-CRP at 2.5 mg/L, and the note reflects that distinction.

HANS does cross-panel pattern synthesis automatically. Elevated Lp-PLA2 or MPO alongside high small dense LDL particles on NMR lipoprofile gets flagged as an urgent arterial risk combination — the pattern associated with highest cardiovascular event risk. HANS catches it consistently.

Longitudinal tracking shows whether Lp-PLA2 and MPO are trending down with treatment. This is the critical question for assessing intervention effectiveness. HANS documents the trend alongside the interpretation.

HANS also integrates with the BaleDoneen risk assessment framework, incorporating these markers into the overall cardiovascular risk score appropriately.

FAQ

Should I order Lp-PLA2 and MPO together or separately? Order them together. Lp-PLA2 reflects macrophage-derived inflammation; MPO reflects neutrophil-derived oxidative stress. Together they give the complete arterial inflammation picture.

How often should I recheck these markers? Every 6-12 months. With aggressive diet, supplement, and lifestyle intervention, meaningful change may appear at 6 months. Otherwise annual monitoring is appropriate.

Do these markers replace hs-CRP? No. They complement it. Start with hs-CRP as a screen; add Lp-PLA2 and MPO when the arterial-specific picture is needed.

Can Lp-PLA2 and MPO be elevated without other cardiovascular risk factors? Yes. This is one of their most clinically important uses: identifying arterial inflammation before traditional risk factors become abnormal.

Do statins lower Lp-PLA2 and MPO? Statins modestly reduce Lp-PLA2 activity. As noted above, the SOLID-TIMI 52 trial (PMID 25173516) showed that pharmacological inhibition of Lp-PLA2 alone doesn't prevent cardiovascular events — reinforcing that comprehensive inflammation reduction matters more than targeting any single marker.

Are these markers covered by insurance? Coverage varies. Lp-PLA2 (the PLAC test) has specific covered indications with some insurers. MPO coverage is less consistent. Out-of-pocket cost is reasonable for the clinical value in FM cardiovascular assessments.

---

References

1. Razban MM et al. "The relationship between serum levels of hs-CRP and coronary lesion severity." Clujul Med. 2016;89(3):352-357. PMID 27547050.

2. Zalewski A, Macphee C. "Role of lipoprotein-associated phospholipase A2 in atherosclerosis: biology, epidemiology, and possible therapeutic target." Arterioscler Thromb Vasc Biol. 2005 May;25(5):923-31. PMID 15557304.

3. Lp-PLA2 Studies Collaboration. "Lipoprotein-associated phospholipase A2 and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies." Lancet. 2010 Jan 9;375(9725):1536-44. PMID 20031397. [Lp-PLA2 predicts events independently of hs-CRP and traditional risk factors.]

4. O'Donoghue ML et al.; SOLID-TIMI 52 Investigators. "Effect of darapladib on major coronary events after an acute coronary syndrome: the SOLID-TIMI 52 randomized clinical trial." JAMA. 2014 Sep 10;312(10):1006-15. PMID 25173516. [Darapladib did not reduce events; drug-specific failure, not a marker validity failure.]

5. Abdo AI et al. "Low-density lipoprotein modified by myeloperoxidase oxidants induces endothelial dysfunction." Redox Biol. 2017 Oct;13:623-632.

6. Aviram M et al. "Pomegranate juice flavonoids inhibit low-density lipoprotein oxidation and cardiovascular diseases: studies in atherosclerotic mice and in humans." Drugs Exp Clin Res. 2002;28(2-3):49-62. PMID 12224378.

---

Want to streamline your cardiovascular risk assessment workflow? See HANS pricing and features to learn how HANS can help you interpret inflammatory markers faster and more accurately.